Skip to content
COYACoya Therapeutics, Inc.

Earnings

When Coya Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

19 quarters. Mar 31, 2022 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 15, before the open

Mon, Mar 15, 2027in 118 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 15 – Apr 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$3.96M
Revenue, change from a year earlier: Q3 2026 −93.4%, Q2 2026 +49.0%, Q1 2026 −2.6%, Q4 2025 +202,768.8%
Net income
-$5.71M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$234.13K−93.4% vs Q3 2025

Latest results

  1. Q3 2026Nov 10, 2026, before the openThe release5.3%by the close of Nov 10
    Revenue
    $234.13K
    −93.4%
    Net income
    -$10.62M
    N/M
    EPS
    -$0.45
    N/M
    Read · nothing to show
  2. Q2 2026Aug 11, 2026, before the openThe release+3.8%by the close of Aug 11
    Revenue
    $243.75K
    +49.0%
    Net income
    -$6.64M
    N/M
    EPS
    -$0.28
    N/M
  3. Q1 2026May 12, 2026, before the openThe release+2.9%by the close of May 12
    Revenue
    $251.15K
    −2.6%
    Net income
    -$7.21M
    N/M
    EPS
    -$0.32
    N/M
  4. Q4 2025Mar 16, 2026, before the openThe release0.8%by the close of Mar 16
    Revenue
    $3.96M
    +202,768.8%
    Net income
    -$5.71M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 10, 2026 · pre-marketNov 10, 202641 d10-Q$234.13K−93.4%-$0.455.3%
Q2 2026Jun 30, 2026Aug 11, 2026 · pre-marketAug 11, 202642 d10-Q$243.75K+49.0%-$0.28+3.8%
Q1 2026Mar 31, 2026May 12, 2026 · pre-marketMay 12, 202642 d10-Q$251.15K−2.6%-$0.32+2.9%
FY 2025
Q4 2025derivedDec 31, 2025Mar 16, 2026 · pre-marketMar 16, 202675 d10-K$3.96M+202,768.8%—0.8%
Q3 2025Sep 30, 2025Nov 12, 2025 · pre-marketNov 12, 202543 d10-Q$3.56M—-$0.13+0.5%
Q2 2025Jun 30, 2025Aug 12, 2025 · pre-marketAug 12, 202543 d10-Q$163.62K−95.2%-$0.361.0%
Q1 2025Mar 31, 2025May 13, 2025 · pre-marketMay 13, 202543 d10-Q$257.88K+103.3%-$0.445.6%
FY 2024
Q4 2024derivedDec 31, 2024Mar 18, 2025 · pre-marketMar 18, 202577 d10-K$1.95K−100.0%—3.9%
Q3 2024Sep 30, 2024Nov 6, 2024 · pre-marketNov 6, 202437 d10-Q$0.00—-$0.26+6.9%
Q2 2024Jun 30, 2024Aug 12, 2024 · pre-marketAug 12, 202443 d10-Q$3.43M—-$0.19—
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q$126.84K—-$0.353.0%
Earlier years, FY 2022 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 10, 2026454478
10-QAug 11, 2026343481
10-QMay 12, 2026218201
10-KMar 16, 2026107281
10-QNov 12, 2025276058
10-QAug 12, 2025106934
10-QMay 13, 2025069824
10-KMar 18, 2025040782
10-QNov 6, 2024121837
10-QAug 12, 2024095075

Provenance

ProvenanceData status and checks

Coya Therapeutics, Inc. · CIK 1835022 · Engraved from SEC EDGAR